ASK REDCHAT ANYTHING ABOUT ESPERION THERAPEUTICS, INC.
Esperion Therapeutics, Inc. (NASDAQ: ESPR)
Listen to this Section
$3.16
+0.0100
(
+0.32% )
0.5K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| Nexletol (bempedoic acid)DetailsHeterozygous familial hypercholesterolemia, Atherosclerotic cardiovascular disease , Hypercholesterolemia |
Approved |
| Nexlizet (bempedoic acid and ezetimibe)DetailsHypercholesterolemia, Atherosclerotic cardiovascular disease , Heterozygous familial hypercholesterolemia, Cardiovascular risk reduction |
Approved |
Market Data
| Open |
$3.16 |
| Previous Close |
$3.15 |
| Volume |
0.5K |
| Market Cap |
$811.73M |
| Day Range |
$3.16 - $3.17 |
| 52 Week Range |
$0.95 - $4.18 |
| Shares Outstanding |
257.69M |
| Change % |
+0.32% |
| Net Change |
▲ 0.0100 |
| Insider Ownership |
0.00% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| IPO Year | 2013 |
| Country | United States |
| Underwriter | IPO Intelligence Only |
Insider Ownership Transactions
Total Amount Purchased:
-1,294,677.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2023-08-09 |
Sale |
-44650.00 |
Foody Joanne M. |
SEC Filings
| Form Type |
Description |
Pages |
Date |
| 10-q |
Quarterly Reports |
72 |
Nov 06, 2025 |
| 8-k |
8K-related |
13 |
Nov 06, 2025 |
| 8-k |
8K-related |
14 |
Nov 04, 2025 |
| 4 |
Insider transactions |
2 |
Oct 20, 2025 |
| 8-k |
8K-related |
18 |
Oct 08, 2025 |
| 8-k |
8K-related |
39 |
Oct 07, 2025 |
| 4 |
Insider transactions |
2 |
Sep 18, 2025 |
| 4 |
Insider transactions |
2 |
Sep 18, 2025 |
| 4 |
Insider transactions |
1 |
Sep 18, 2025 |
| 10-q |
Quarterly Reports |
72 |
Aug 13, 2025 |